Study name | Dong MX 2018 |
Title | Integrated analysis reveals altered lipid and glucose metabolism and identifies NOTCH2 as a biomarker for Parkinson's disease related depression |
Overall design | The aim of this study was to investigate the altered metabolic pathways of Parkinson's disease-related depression (PDD) in plasma and to identify potential biomarkers for clinical diagnosis. Consecutive patients with Parkinson's disease (PD) were recruited, clinically assessed, and patients with PDD identified. Fasting plasma samples were collected from 99 patients and differentially expressed metabolites and proteins between patients with PDD (Parkinson's disease with depression group, n=23) and PD (Parkinson's disease without depression group, n=40) were identified using non-targeted liquid chromatography-mass spectrometry (LC-MS)-based metabolomics and tandem mass tag (TMT)-based proteomics analysis, followed by an integrated analysis. |
Study Type  | Type1;
|
Data available | Unavailable |
Organism | Human;
|
Categories of depression | Depressive disorder; Depression with comorbidity; Depression with comorbidity;
|
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 17 |
Sample size | 63 |
Tissue | Peripheral; Blood; Plasma;
|
Platform | MS-based; LC-MS: Waters UPLC I-class system with binary solvent delivery manager (Waters Corporation, Milford, USA); |
PMID | 30233306 |
DOI | 10.3389/fnmol.2018.00257 |
Citation | Dong MX, Feng X, Xu XM, et al. Integrated analysis reveals altered lipid and glucose metabolism and identifies NOTCH2 as a biomarker for Parkinson's disease related depression. Front Mol Neurosci. 2018;11:257. |
Metabolite | Bilirubin;
N-Acetyl-L-glutamic acid;
Ribitol;
Decanoylcarnitine;
Lipoamide;
11Z-Eicosenoic acid;
Thiamine;
MG(0:0/20:4(5Z,8Z,11Z,14Z)/0:0);
Tetrahydrocortisol;
Deoxycholic acid 3-glucuronide;
LysoPC(20:3/0:0);
Eicosapentaenoic acid;
4a-Carboxy-4b-methyl-5a-cholesta-8,24-dien-3b-ol;
Ganglioside GM1 (d18:1/18:1(11Z));
Phenyl acetate;
DG(20:2n6/0:0/20:5n3);
Tetracosatetraenoic acid (24:4n-6);
Celastrol;
[6]-Gingerdiol 4'-O-beta-D-glucopyranoside;
DG(14:1(9Z)/18:3(6Z,9Z,12Z)/0:0);
PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z));
Heme;
Estradiol acetate glucuronide;
Secalciferol;
Vanillactic acid;
Cetoleic acid;
Didymin;
1-Heptadecanoylglycerophosphoethanolamine;
PA(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z));
Melledonol;
S-Adenosylmethionine;
1-(alpha-Methyl-4-(2-methylpropyl)benzeneacetate)-beta-D-Glucopyranuronic acid;
10Z-Nonadecenoic acid;
TG(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/20:3(8Z,11Z,14Z))[iso3];
CPA(18:0/0:0);
Fusarin C;
Ubiquinol-10;
Thyroxine glucuronide;
Galactan;
15-HETE;
Stearoyllactic acid;
Dihydrothymine;
3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid;
18-Hydroxycorticosterone;
Dolichosterone;
TG(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z));
2-Methylbacteriohopane-32,33,34,35-tetrol;
2-Methoxy-estradiol-17b 3-glucuronide;
Dehydrotomatine;
Docosapentaenoic acid (22n-3);
Retinyl ester;
Ramiprilat;
N-Glycoloylganglioside GM1;
Ganglioside GD3 (d18:1/23:0);
Hydroxyvalerylcarnitine;
3-[[5-Methyl-2-(1-methylethyl)cyclohexyl]oxy]-1,2-propanediol;
Triterpenoid;
15H-11,12-EETA;
2,4,12-Octadecatrienoic acid isobutylamide;
Dihomo-gamma-linolenic acid;
Capsianoside II;
Cer(d18:0/24:0);
6alpha-Glucuronosylhyodeoxycholate;
1,11-Undecanedicarboxylic acid;
PE(18:1(9Z)/16:0);
2-Oleoylglycerophosphocholine;
Ganglioside GD3 (d18:1/16:0);
3-Hydroxydodecanoic acid;
(3a,5b,7a,12a)-24-[(carboxymethyl)amino]-1,12-dihydroxy-24-oxocholan-3-yl-b-D-Glucopyranosiduronic acid;
Ganglioside GT3 (d18:0/12:0);
Tetrahydroaldosterone-3-glucuronide;
3-Oxo-4,6-choladienoic acid;
VPGPR Enterostatin;
Ganglioside GD2 (d18:0/18:1(9Z));
PC(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z));
ubiquinone-8;
LysoPE(0:0/20:5(5Z,8Z,11Z,14Z,17Z));
PE(18:2(9Z,12Z)/24:0);
LysoPC(20:5(5Z,8Z,11Z,14Z,17Z));
Ganglioside GM1 (d18:1/24:0);
Tetrahydrobiopterin;
LysoPE(0:0/22:5(4Z,7Z,10Z,13Z,16Z));
PC(18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z));
13-Hydroxy-5'-O-methylmelledonal;
PC(15:0/20:5(5Z,8Z,11Z,14Z,17Z));
|